Since there are differences in receptor binding affinity, signaling, and bioactivity profiles between IL-17F and IL-17A, the functional program of Th17s in CLL tissue microenvironments might be distinct from that seen in healthy subjects. The gene discussed is IL17F; the disease is B-cell chronic lymphocytic leukemia.